- Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
- Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
- Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
- Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test is an affordable, accessible blood test that detects cancer in dogs.

Advances in Liquid Biopsy for Glioblastoma Diagnosis and Monitoring through Nucleosome Epigenetic Modifications Tracking
- Share
- Tweet
- Share on Facebook
- Share


Paper titled: Advances in Liquid Biopsy for Glioblastoma Diagnosis and Monitoring through Nucleosome Epigenetic Modifications Tracking
Priscilla Van den Ackerveken, Jonathan Decarpentrie, Clotilde Hannart, Nathalie Hardat, Matteo Riva, Nathalie Donis, Fabienne George, Lionel d’Hondt, Jonathan Douxilfs, Marielle Herzog
Presented at ISMRC 2025
Related Articles
- Poster & Publications
Liquid biopsy: measuring circulating H3K27Me3-nucleosomes in Lung Cancer patients is a strong prognostic biomarker and a potential aid in treatment selection
- Poster & Publications
Early detection of stage I/II Lung Cancer by immunoassay of crosslinked plasma cell free nucleosomes
- Share
- Tweet
- Share on Facebook
- Share
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields